Skip to main content

Cancer treatment maker BioCold Genesys lands $22M in funds

Cold Genesys, Inc., a biopharmaceutical company developing novel immunotherapies used to treat cancer, has closed on $22 million in financing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.